| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFa2 |
| Uniprot No | P59665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-94aa |
| 氨基酸序列 | MRTLAILAAILLVALQAQAEPLQARADEVAAAPEQIAADIPEVVVSLAWDESLAPKHPGSRKNMACYCRIPACIAGERRYGTCIYQGRLWAFCC |
| 预测分子量 | 37.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFa2重组蛋白的3篇示例文献(内容为模拟概括，实际文献需查询数据库)：
1. **文献名称**：Expression and antimicrobial activity of recombinant human DEFa2 in Escherichia coli
**作者**：Smith J, et al.
**摘要**：研究利用大肠杆菌系统成功表达重组人DEFa2蛋白，并验证其对多种病原菌的抗菌活性，证实其结构稳定性与天然肽相似。
2. **文献名称**：Structural and functional characterization of DEFa2 recombinant protein in inflammatory bowel disease models
**作者**：Li X, et al.
**摘要**：通过体外实验和小鼠结肠炎模型，证明重组DEFa2能通过调节肠道菌群和抑制TLR4通路减轻炎症反应，提示其治疗潜力。
3. **文献名称**：Optimization of DEFa2 recombinant production using yeast expression system
**作者**：Wang Y, et al.
**摘要**：开发基于毕赤酵母的DEFa2重组表达体系，通过密码子优化和发酵条件调控使产量提高3倍，并保留完整的抗菌功能。
建议通过PubMed或Google Scholar以"DEFa2 recombinant protein"、"human defensin alpha 2 expression"等关键词检索真实文献。
DEFa2 (Defensin Alpha 2) is a small cationic peptide belonging to the α-defensin family, a class of evolutionarily conserved antimicrobial proteins integral to innate immunity. These peptides are characterized by a β-sheet-rich structure stabilized by three disulfide bonds, conferring stability against enzymatic degradation. DEFa2 is primarily produced by Paneth cells in the intestinal crypts and neutrophils, playing critical roles in host defense by disrupting microbial membranes through electrostatic interactions with negatively charged pathogens. Beyond direct microbicidal activity, DEFa2 modulates immune responses by recruiting immune cells, promoting cytokine release, and enhancing barrier function.
Recombinant DEFa2 is engineered through heterologous expression systems, such as E. coli or mammalian cell cultures, to overcome challenges in natural extraction, including low yield and contamination risks. Advances in protein folding and purification techniques, notably fusion tag strategies and in vitro refolding, have improved production efficiency. Studies highlight its therapeutic potential against multidrug-resistant bacteria, viruses, and fungi, while its immunomodulatory properties are explored in inflammatory bowel disease (IBD) and cancer therapy. However, clinical translation faces hurdles like optimizing pharmacokinetics and minimizing cytotoxicity. Current research focuses on structural analogs and delivery systems to enhance stability and tissue targeting. DEFa2 exemplifies the convergence of natural immunity and biotechnology, offering a promising scaffold for novel antimicrobial and immunotherapeutic agents.
×
